A Meta-analysis of the effects of intravitreal conbercept as an adjunct before vitrectomy in proliferative diabetic retinopathy

Authors: Si Xia,  Sun Chufeng,  Chen Yue,  Feng Wanyu,  Feng Yufei
DOI: 10.3760/cma.j.cn115989-20200715-00498
Published 2020-09-10
Cite as Chin J Exp Ophthalmol, 2020,38(09): 773-780.

Abstract                               [View PDF] [Read Full Text]

Objective

To evaluate the efficacy and safety of preoperative intravitreal conbercept (IVC) as an adjunct to pars plana vitrectomy (PPV) in the treatment of proliferative diabetic retinopathy (PDR).

Methods

A systematic search in EMbase, PubMed, Cochrane Library, Chinese periodical full text database (CNKI), Wanfang database and VIP database were conducted, studies about the effectiveness and safety of IVC combined with PPV in the management of PDR were collected.Two researchers independently screened the studies according to the inclusion criteria and exclusion criteria, and extracted the data.The quality of the randomized controlled trial (RCT) was evaluated by the modified Jadad scale, and the quality of the cohort study or case-control study was evaluated by the Newcastle Ottawa scale (NOS). Rev Man 5.3 was applied for data analysis.

Results

A total of 11 RCTs, 2 cohort studies and 10 case-control studies involving 1 625 patients and 1 844 eyes were included.The final Jadad score for each RCT was more than 3, and the final NOS score for each cohort study and case-control study was more than 5.The results of Meta-analysis showed that the total effectiveness of treatment was significantly higher in the preoperative IVC group than that in the simple PPV group (RR=1.31, 95% CI: 1.21-1.42, P<0.001). The average operation duration was significantly shorter in the preoperative IVC group compared with that in the simple PPV group (MD=-21.11, 95% CI: -26.39–15.83, P<0.001). The level of VEGF was significantly lower in the preoperative IVC group than that in the simple PPV group (MD=-15.33, 95% CI: -19.40–11.26, P<0.001). Preoperative IVC could reduce the incidences of intraoperative bleeding, iatrogenic retinal breaks, postoperative recurrent vitreous hemorrhage and temporary increase of intraocular pressure, with statistically significant differences between them (all at P<0.05).

Conclusions

Preoperative intravitreal injection of conbercept shows better effect and safer than vitrectomy alone, and it has no serious side effect.

Key words:

Conbercept; Proliferative diabetic retinopathy; Vitrectomy; Vascular endothelial growth factor; Meta-analysis

Contributor Information

Si Xia
Department of Pharmacy, Peking University People’s Hospital, Beijing 100044, China
Sun Chufeng
Department of Pharmacy, Peking University People’s Hospital, Beijing 100044, China
Chen Yue
Department of Pharmacy, Peking University People’s Hospital, Beijing 100044, China
Feng Wanyu
Department of Pharmacy, Peking University People’s Hospital, Beijing 100044, China
Feng Yufei
Department of Pharmacy, Peking University People’s Hospital, Beijing 100044, China
(Read 100 times, 1 visits today)
Updated: December 15, 2022 — 2:49 am